Altre lingue Viridian Therapeutics, Inc.

Azioni

VRDN

US92790C1045

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
12,88 ^USD	+1,42%		-11,78%	-40,86%

21/03	VIRIDIAN THERAPEUTICS, INC. : B. Riley mantiene la raccomandazione Buy	ZM
28/02	VIRIDIAN THERAPEUTICS, INC. : Wedbush è per il Buy	ZM

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Foghorn Therapeutics Names Kristian Humer CFO	16/04
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/04
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm	29/03
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06/03
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05/03
Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Posts Q4 Revenue $72,000	27/02
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results	27/02
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	19/02
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	16/02
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)	07/02
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	06/02
Viridian Therapeutics Prices Common Stock Offering at $21 per Share	18/01
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock	18/01
Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours	17/01
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock	17/01
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference	08/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Viridian Therapeutics, Inc.

Azioni

VRDN

US92790C1045

Altre lingue

Filtri